New Delhi, Jan 10
RANBAXY Laboratories Ltd has entered into a co-marketing agreement with Ferring International of Switzerland for Desmopressin, which is used in treatment of urology-related disorders.
According to a company statement, the drug would be useful for both paediatric and geriatric patients.
Desmopressin, an original research product of Ferring International, is available in tablets and sprays, and is currently marketed by the company's subsidiary in India.
This new co-marketing arrangement aims to leverage Ranbaxy's significant marketing and distribution strengths to maximise patient coverage within the country. The product will be sold under the brand name Adiuretin.
Mr Sanjeev Dani, Regional Director (India and Middle East), Ranbaxy, said: "This is a strategic move by Ranbaxy to in-licence differentiated products for the Indian market." The Ranbaxy scrip closed at Rs 393.75 on the BSE on Tuesday.